Mark Levandovsky, MD
Hematology & Oncology Physician · Grand Junction, CO
Mark Levandovsky, MD is a hematology & oncology physician with a practice address in Grand Junction, Colorado, and NPI 1922267285, issued on Jun 3, 2008. Check the license (Colorado 0055418, as entered in NPPES) on the Colorado Medical Board; the Medicare figures below come from public CMS files.
- Name
- Mark Levandovsky
- Credential
- MD
- Primary taxonomy
- Hematology & Oncology Physician 207RH0003X
- License numbers
- 0055418 CO
6634 AK
236596 NY
Self-reported in NPPES; status is on the state search - Practice location
- 750 Wellington Ave, Grand Junction, CO 81501
- Phone
- (970) 298-7500
- Enumerated
- Jun 3, 2008
- Record last updated
- Mar 4, 2016 (not updated in 10 years: call before relying on the address or phone)
- Entity
- Type 1 · individual
8 nearest hematology & oncology physician records → All 212 in Colorado → Look up another NPI →
Also registered at 750 Wellington Ave
A shared address usually means a shared clinic or building; it does not show who employs whom.
- Basheal Agrawal, M.D.Neurological Surgery Physician1154365153
- Michelle Akcar, PHARMDPharmacist1205272283
- Michael Appel, PHARMDOncology Pharmacist1487822540
- Scott Donohue, RPHOncology Pharmacist1376981431
- Richard Gibson, MDHematology & Oncology Physician1396721973
- Lucas Gilbride, MDRadiation Oncology Physician1891109559
Verify Mark Levandovsky in five checks
- 1IdentityNPI record in CMS NPPESNPI lookupConfirmed in NPPES
- 2LicenseActive license and public ordersColorado Medical Board
Search for license 0055418Check the board - 3Other statesLicenses and actions elsewhereDocInfo (FSMB)Not checked
- 4ExclusionsMedicare and Medicaid bansHHS-OIG exclusion listNot checked
- 5CertificationBoard certificationABMS AOA NCCPA AANPNot checked
59% fewer Medicare Part D claims than the average hematology & oncology physician in 2024
360 Medicare Part D claims for 20 beneficiaries, against an average of 877 among the 10,784 providers of this specialty who prescribed in Part D. Brand-name drugs were 28% of claims. 12 claims were for opioids.
Most prescribed
- Atorvastatin Calcium32 claims
- Repatha Sureclick29 claims
- Amlodipine Besylate17 claims
- Jardiance17 claims
- Losartan Potassium13 claims
- Ozempic13 claims
Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.
Industry payments in 2024: $90.77
4 payments; by number, the most common kind was food and beverage; the largest payer was Amgen Inc. The 8,560 providers of this specialty with any payment received $7,481.41 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.
Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.
Mark Levandovsky among 212 hematology & oncology physician records in Colorado
Mark Levandovsky, MD is one of 212 hematology & oncology physician records with a practice address in Colorado. 77% of them appear in a Medicare file (Part D prescribing, MIPS, Open Payments or Medicare group billing); this one does. Its NPI, issued in 2008, is newer than 66% of them.
- NPI issued2008 · 66% of these records are older, 31% newer
- In a Medicare fileYes · 77% of these records are
- In the CMS Doctors and Clinicians fileNo · 71% of these records are
- Record last updated2016 · 59% of these records were not updated in five years or more
Source: CMS NPPES, file of Aug 9, 2026, every record with primary taxonomy 207RH0003X and a Colorado practice address; Medicare files: CMS Part D Prescribers 2024, MIPS 2023, Open Payments 2024, Doctors and Clinicians (data.cms.gov).
Hematology & Oncology Physician providers in Colorado
There are 212 hematology & oncology physician records in Colorado.
All 212 in Colorado → Every provider in Grand Junction → Hematology & Oncology Physician nationwide →
The 8 hematology & oncology physician records with the nearest ZIP codes
- Richard Gibson, MDGrand Junction, CO 815011396721973
- Wallace JonesGrand Junction, CO 815011255835724
- Irene Minkoff, MDGrand Junction, CO 815011427004142
- Alicia Swink, M.D.Grand Junction, CO 815011235573270
- Heather Steele, M.D.Grand Junction, CO 815051538209606
- Joanne Virgilio, DOGrand Junction, CO 815051760468342
- Dorinda Rouch, MDDelta, CO 814161750381513
- Christine Urbanski, MDDelta, CO 814161548201528
Common questions
What is Mark Levandovsky, MD's NPI number?
Mark Levandovsky, MD's National Provider Identifier (NPI) is 1922267285, issued on Jun 3, 2008. An NPI identifies a provider in billing; it is not a license.
Where is Mark Levandovsky, MD located?
The NPPES record lists a practice address at 750 Wellington Ave, Grand Junction, CO, 81501. Phone: (970) 298-7500. Providers update this record themselves, so call before visiting.
How can I verify Mark Levandovsky, MD's license?
NPPES lists Colorado license number 0055418, as entered by the provider. Search the Colorado Medical Board at https://dpo.colorado.gov/Medical. The NPPES record confirms identity only; the state search shows license status, expiration and public orders.
How much does Mark Levandovsky, MD prescribe under Medicare Part D?
In 2024, Mark Levandovsky, MD had 360 Medicare Part D claims for 20 beneficiaries; the average among hematology & oncology physician prescribers was 877. Part D covers Medicare prescriptions only.
Source: CMS National Plan and Provider Enumeration System (NPPES), file of Aug 9, 2026 (NPPES files on CMS.gov); NUCC Health Care Provider Taxonomy. Medicare files from data.cms.gov. An NPI identifies who bills; it is not a license.
Figures on PlainDoctor are read from the federal files each page names (CMS NPPES, Medicare Part D, MIPS, Open Payments; the HHS-OIG exclusion list only as counts) and from Census population estimates, with the file date shown beside them. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of Aug 9, 2026.